Ashwin Ganti1, Anish Raman1, Aryan Shay1, Hannah N Kuhar1, Samuel R Auger1, Tirth Patel2, Edward C Kuan3, Aidnag Z Diaz4, Pete S Batra2, Bobby A Tajudeen2. 1. Rush Medical College, Rush University Medical Center, Chicago, Illinois, U.S.A. 2. Department of Otorhinolaryngology-Head and Neck Surgery, Rush Center for Skull Base and Pituitary Surgery, Rush University Medical Center, Chicago, Illinois, U.S.A. 3. Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine Medical Center, Orange, California, U.S.A. 4. and Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: The purpose of this study was to investigate the association of demographic factors, tumor stage, and treatment modalities for overall survival in patients with sinonasal mucosal melanoma (SNMM). STUDY DESIGN: Retrospective database review. METHODS: The National Cancer Database was queried for patients of all ages with SNMM between 2004 and 2015. Univariate Kaplan-Meier and multivariate Cox regression analyses were performed to evaluate the association of suspected prognostic factors with overall survival. RESULTS: A total of 1,874 patients with SNMM were included in the analysis. The 5-year overall survival was 24%. Prognostic factors associated with decreased survival include advanced age (hazard ratio [HR]: 1.02, 95% confidence interval [CI]: 1.01-1.03), T4 disease (HR: 1.44, 95% CI: 1.09-1.89), and presence of distant metastases (HR: 3.22. 95% CI: 2.06-5.04). Improved survival was associated with surgical resection only when margins were negative (HR: 0.44; 95% CI: 0.30-0.65). In patients with metastatic disease, administration of immunotherapy (HR: 0.14; 95% CI: 0.04-0.49) was associated with improved survival. Surgical approach, radiotherapy, and chemotherapy were nonsignificant predictors of survival. CONCLUSIONS: This investigation is the largest to date to analyze the association of treatment modalities with overall survival in SNMM. Surgery remains the mainstay of treatment in patients with SNMM. However, administration of immunotherapy may confer survival benefit to patients with metastatic disease. LEVEL OF EVIDENCE: NA Laryngoscope, 2019.
OBJECTIVES/HYPOTHESIS: The purpose of this study was to investigate the association of demographic factors, tumor stage, and treatment modalities for overall survival in patients with sinonasal mucosal melanoma (SNMM). STUDY DESIGN: Retrospective database review. METHODS: The National Cancer Database was queried for patients of all ages with SNMM between 2004 and 2015. Univariate Kaplan-Meier and multivariate Cox regression analyses were performed to evaluate the association of suspected prognostic factors with overall survival. RESULTS: A total of 1,874 patients with SNMM were included in the analysis. The 5-year overall survival was 24%. Prognostic factors associated with decreased survival include advanced age (hazard ratio [HR]: 1.02, 95% confidence interval [CI]: 1.01-1.03), T4 disease (HR: 1.44, 95% CI: 1.09-1.89), and presence of distant metastases (HR: 3.22. 95% CI: 2.06-5.04). Improved survival was associated with surgical resection only when margins were negative (HR: 0.44; 95% CI: 0.30-0.65). In patients with metastatic disease, administration of immunotherapy (HR: 0.14; 95% CI: 0.04-0.49) was associated with improved survival. Surgical approach, radiotherapy, and chemotherapy were nonsignificant predictors of survival. CONCLUSIONS: This investigation is the largest to date to analyze the association of treatment modalities with overall survival in SNMM. Surgery remains the mainstay of treatment in patients with SNMM. However, administration of immunotherapy may confer survival benefit to patients with metastatic disease. LEVEL OF EVIDENCE: NA Laryngoscope, 2019.
Authors: Stephanie Flukes; Shivangi Lohia; Christopher A Barker; Jennifer R Cracchiolo; Ian Ganly; Snehal G Patel; Benjamin R Roman; Jatin P Shah; Alexander N Shoushtari; Viviane Tabar; Akash Shah; Marc A Cohen Journal: Head Neck Date: 2020-08-01 Impact factor: 3.147
Authors: Fernando López; Jatin P Shah; Jonathan J Beitler; Carl H Snyderman; Valerie Lund; Cesare Piazza; Antti A Mäkitie; Orlando Guntinas-Lichius; Juan P Rodrigo; Luiz P Kowalski; Miquel Quer; Ashok Shaha; Akihiro Homma; Alvaro Sanabria; Renata Ferrarotto; Anne W M Lee; Victor H F Lee; Alessandra Rinaldo; Alfio Ferlito Journal: Adv Ther Date: 2022-03-30 Impact factor: 4.070
Authors: Olena Klymenko; Anna Maria Stefanie Buchberger; Barbara Wollenberg; Klaus-Dietrich Wolff; Victoria Kehl; Stephanie E Combs; Anja Pickhard; Steffi U Pigorsch Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639
Authors: Tiffany N Chao; Edward C Kuan; Charles C L Tong; Michael A Kohanski; M Sean Grady; James N Palmer; Nithin D Adappa; Bert W O'Malley Journal: J Neurol Surg B Skull Base Date: 2020-02-07